| Registered Number:10046614 |
For the year ended 30 September 2024
England and Wales
Unaudited Financial Statements
For the year ended 30 September 2024
Global Pharma Direct Ltd
Contents Page
1
Statement of Financial Position
2 to 3
Notes to the Financial Statements
Global Pharma Direct Ltd
Statement of Financial Position
2023
2024
| Property, plant and equipment |
196,184
184,847
2
196,184
184,847
-
23,163
3
| Trade and other receivables |
74,319
62,299
4
74,617
| Cash and cash equivalents |
47,742
133,204
148,936
| Trade and other payables: amounts falling due within one year |
(92,264)
(67,892)
5
56,672
65,312
Net current assets
| Total assets less current liabilities |
261,496
241,519
| Trade and other payables: amounts falling due after more than |
| one year |
(57,021)
(90,463)
6
171,033
Net assets
184,498
1,000
1,000
170,033
183,498
171,033
184,498
Shareholders' funds
| For the year ended 30 September 2024 the company was entitled to exemption from audit under Section 477 of the Companies Act 2006 relating to small companies. |
| The members have not required the company to obtain an audit of its financial statements for the year ended 30 September 2024 in accordance with Section 476 of the Companies Act 2006 |
| The directors acknowledge their responsibilities for:a) ensuring that the company keeps proper accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
| b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each |
| financial year and of its profit or loss for each financial year in accordance with the requirements of Section 394 and 395 and |
| which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as |
| applicable to the company. |
| In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered. |
| The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. |
| Mr Amjid Malik Khan Director |
| These financial statements were approved and authorised for issue by the Board on 17 February 2025 and were signed by: |
| The notes form part of these financial statements |
1 of 3
For the year ended 30 September 2024
Global Pharma Direct Ltd
Notes to the Financial Statements
Statutory Information
| Global Pharma Direct Ltd is a private limited company, limited by shares, domiciled in England and Wales, registration number |
| 10046614. |
Station Works, Station Road,
Oxenby Drive, Langworth
Lincoln
Linconlshire
LN3 5BB
| The presentation currency is £ sterling. |
Basis of preparing the financial statements
| These financial statements have been prepared in accordance with the provisions of Section 1A of Financial Reporting |
| Standard 102 ''The Financial Reporting Standard applicable in the UK and Republic of Ireland'' and the Companies Act 2006. |
| The financial statements have been prepared under the historical costs convention as modified by the revaluation of certain |
| assets. |
| 2. Property, plant and equipment |
Motor Vehicles
257,907
104,546
36,727
116,634
28,724
28,724
-
-
116,634
36,727
133,270
286,631
| Provision for depreciation and impairment |
73,060
58,853
14,207
-
Charge for year
17,387
14,883
2,504
-
90,447
73,736
16,711
-
116,634
20,016
59,534
196,184
116,634
22,520
45,693
184,847
2023
2024
23,163
-
2 of 3
For the year ended 30 September 2024
Global Pharma Direct Ltd
Notes to the Financial Statements Continued
| 4. Trade and other receivables |
2023
2024
62,299
74,319
| 5. Trade and other payables: amounts falling due within one year |
2023
2024
29,698
5,768
9,519
-
28,675
86,496
67,892
92,264
| 6. Trade and other payables: amounts falling due after more than one year |
2023
2024
| Bank loans and overdraft (secured) |
7,747
-
-
21,203
82,716
35,818
90,463
57,021
| 7. Average number of persons employed |
During the year the average number of employees was 0
3 of 3